Single molecule counting (SMC™) technology enables precise measurement of molecules at levels previously undetectable, down to the femtogram/mL levels, allowing researchers to identify new biomarkers or assist in therapeutic development with an improved view of efficacy, safety and time course studies. Find out more in this video webinar from Millipore Sigma (MA, USA).
BioAgilytix (NC, USA) have announced their partnership with Sword Bio (IL, USA), to expand their bioanalytical services to include Sword Bio’s detection platform for immunoassays.
In this interview we talk to Stephane Moreau (Shimadzu, Europe) about his research into nSMOL monoclonal antibody analysis. Stephane discusses the benefits of this technique in comparison with traditional technology like immunoassays.
Issue 22 of Bioanalysis volume 9 is now available, including an editorial article on immunogenicity and biomarkers, a conference report from the 8th Japan Bioanalysis Forum and the 2017 White Paper on Recent issues in Bioanalysis.
Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol
This article looks at a new electrochemiluminescence immunoassay developed to measure certolizumab pegol levels in human plasma. Learn more in this article from Bioanalysis.
Development and validation of an impedance biosensor for point-of-care detection of vascular cell adhesion molecule-1 toward lupus diagnostics
Learn more about the potential future application of point-of-care biosensors in clinical and at-home monitoring of autoimmune diseases, such as lupus in this article from Future Science OA
New kit promises to reduce costs and improve productivity of insulin bioanalysis workflows across biopharmaceutical research and sports anti-doping industries.
Bioanalysis and Bioanalysis Zone were proud to support the WRIB Poster Awards at the 11th WRIB – here we feature the three winning posters.
3-(4-Hydroxyphenyl)propionic acid: the forgotten detection substrate for ligand-binding assay-based bioanalysis
In this review article the authors outline the increase in sensitivity and dynamic range when using fluorogenic 3-(4-hydroxyphenyl)propionic acid in preference of other conventional colorimetric ELISA, LBA technologies and LC-MS assays.
The authors demonstrate how the relationship between academia and not-for-profit organizations with large pharma and emerging biotech companies has shifted toward a more collaborative effort in bringing new therapies to the forefront.